Acceleron Pharma To Host Educational Webcast Series With Clinical Thought Leaders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that it plans to host and webcast a series of online seminars with thought-leading experts in diseases for which sotatercept and luspatercept (ACE-536) are being developed. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept and luspatercept in patients with lower-risk MDS, beta-thalassemia and end-stage renal disease with mineral and bone disorder.
Help employers find you! Check out all the jobs and post your resume.